A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

Stopped early · Phase 1

Conditions studied: Neoplasms, Lymphoma, Non-Hodgkin

In brief

AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.

Key facts

Study ID

NCT00147485

Run by

Pfizer

People needed

37

Starts

2004-12-01

Expected to finish

2007-08-01

Last updated by the study team

2008-08-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumors or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition
• Adequate blood cell counts, kidney function and liver function and and ECOG score of 0 or 1.

You may not qualify if…

• Prior high-dose chemotherapy requiring hemapoietic stem cell rescue
• Previous radiation therapy to >25% of the bone marrow
• Active or unstable cardiac disease or history of heart attack within 6 months

Where it is running

• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.